Collegium Pharmaceutical, Inc COLL
We take great care to ensure that the data presented and summarized in this overview for COLLEGIUM PHARMACEUTICAL, INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding COLL
View all-
Black Rock Inc. New York, NY5.79MShares$187 Million0.0% of portfolio
-
Rubric Capital Management LP New York, NY3MShares$96.8 Million2.57% of portfolio
-
Eventide Asset Management, LLC Boston, MA2.64MShares$85.2 Million1.67% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.25MShares$72.5 Million0.0% of portfolio
-
Invesco Ltd. Atlanta, GA1.63MShares$52.7 Million0.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.62MShares$52.1 Million0.08% of portfolio
-
Principal Financial Group Inc Des Moines, IA1.57MShares$50.8 Million0.03% of portfolio
-
State Street Corp Boston, MA1.38MShares$44.4 Million0.0% of portfolio
-
Fuller & Thaler Asset Management, Inc. San Mateo, CA1.37MShares$44.2 Million0.16% of portfolio
-
Dimensional Fund Advisors LP Austin, TX909KShares$29.3 Million0.01% of portfolio
Latest Institutional Activity in COLL
Top Purchases
Top Sells
About COLL
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Insider Transactions at COLL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 09
2025
|
John Gordon Freund Director |
SELL
Open market or private sale
|
Direct |
6,601
-8.54%
|
$198,030
$30.62 P/Share
|
|
Jun 09
2025
|
John Gordon Freund Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+16.26%
|
$195,000
$13.45 P/Share
|
|
May 15
2025
|
John Gordon Freund Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,791
+13.59%
|
-
|
|
May 15
2025
|
Rita J. Balice Gordon Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,791
+14.82%
|
-
|
|
May 15
2025
|
Garen G Bohlin Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,791
+13.59%
|
-
|
|
May 15
2025
|
Nancy Lurker Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,791
+30.31%
|
-
|
|
May 15
2025
|
John A. Fallon Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,791
+13.16%
|
-
|
|
May 15
2025
|
Carlos V Paya Director |
BUY
Grant, award, or other acquisition
|
Direct |
19,582
+50.0%
|
-
|
|
May 15
2025
|
Gino Santini Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,791
+10.28%
|
-
|
|
Mar 21
2025
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
18,881
-15.41%
|
$566,430
$30.03 P/Share
|
|
Mar 21
2025
|
Colleen Tupper EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,396
-3.92%
|
$191,880
$30.03 P/Share
|
|
Mar 20
2025
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,927
-1.55%
|
$57,810
$30.0 P/Share
|
|
Mar 20
2025
|
Colleen Tupper EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,206
-0.73%
|
$36,180
$30.0 P/Share
|
|
Mar 17
2025
|
David Dieter EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
68,449
+50.0%
|
-
|
|
Mar 14
2025
|
Colleen Tupper EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
977
-0.59%
|
$29,310
$30.0 P/Share
|
|
Mar 14
2025
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,255
-1.78%
|
$67,650
$30.0 P/Share
|
|
Mar 11
2025
|
Colleen Tupper EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,445
-5.95%
|
$313,350
$30.01 P/Share
|
|
Mar 07
2025
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,348
-1.63%
|
$70,440
$30.0 P/Share
|
|
Mar 07
2025
|
Colleen Tupper EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,504
-0.85%
|
$45,120
$30.0 P/Share
|
|
Mar 06
2025
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
18,682
-6.53%
|
$560,460
$30.0 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 530K shares |
|---|---|
| Exercise of conversion of derivative security | 82.5K shares |
| Payment of exercise price or tax liability | 101K shares |
|---|---|
| Open market or private sale | 217K shares |